Sectors
SYRE
Spyre Therapeutics, Inc.
87.92
1 x 66.06
4 x 113.92
bid
ask
-
2.44
2.70%
02:11 PM
timesize
| Ytd | 168.39% | |
| 1y | 433.20% |
87.05
day range
90.97
14.51
52 week range
110.17
| Open | 89.15 | Prev Close | 90.36 | Low | 87.05 | High | 90.97 | Mkt Cap | 7.75B |
| Vol | 819.14K | Avg Vol | 1.30M | EPS | -1.92 | P/E | N/A | Forward P/E | -26.31 |
| Beta | 3.03 | Short Ratio | 12.43 | Inst. Own | 110.67% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-03 | 50-d Avg | 98.47 | 200-d Avg | 60.37 | 1yr Est | 119.71 |
| Income Statement | |||
| Operating Expenses | 41.64M | ||
| Research and Development Expense | 65.50M | ||
| Selling, General and Administrative Expense | 16.14M | ||
| Operating Income | -41.64M | ||
| Net Income | -36.20M | ||
| Net Income Common Stock | -36.20M | ||
| Net Income Common Stock (USD) | -36.20M | ||
| Consolidated Income | -36.20M | ||
| Earnings per Basic Share | -0.36 | ||
| Earnings per Basic Share (USD) | -0.36 | ||
| Earnings per Diluted Share | -0.36 | ||
| Earning Before Interest & Taxes (EBIT) | -36.20M | ||
| Earning Before Interest & Taxes (USD) | -36.20M | ||
| Weighted Average Shares | 84.73M | ||
| Weighted Average Shares Diluted | 84.73M | ||
| Balance Sheet | |||
| Cash and Equivalents | 162.01M | ||
| Cash and Equivalents (USD) | 162.01M | ||
| Investments | 983.34M | ||
| Investments Current | 983.34M | ||
| Current Assets | 1.17B | ||
| Total Assets | 1.17B | ||
| Current Liabilities | 63.30M | ||
| Total Liabilities | 71.86M | ||
| Accumulated Retained Earnings (Deficit) | -1.23B | ||
| Accumulated Other Comprehensive Income | -2.40M | ||
| Shareholders Equity | 1.10B | ||
| Shareholders Equity (USD) | 1.10B | ||
| Liabilities Non-Current | 8.56M | ||
| Trade and Non-Trade Payables | 5.77M | ||
| Cash Flow | |||
| Net Cash Flow from Financing | 432.60M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 64.82M | ||
| Net Cash Flow - Business Acquisitions and Disposals | 40.00M | ||
| Issuance (Purchase) of Equity Shares | 455.82M | ||
| Net Cash Flow from Investing | -297.90M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -337.90M | ||
| Net Cash Flow from Operations | -69.88M | ||
| Share Based Compensation | 13.51M | ||